MD Anderson Cancer: Newly Approved Targeted Therapy Sotorasib Prolongs Survival in KRAS G12C-mutated Lung Cancer
June 05, 2021
June 05, 2021
HOUSTON, Texas, June 5 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 4, 2021:
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD . . .
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to researchers from The University of Texas MD . . .